Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Marina Biotech, Inc. (OTC: MRNA).

Full DD Report for MRNA

You must become a subscriber to view this report.


Recent News from (OTC: MRNA)

Marina Biotech Announces a New Publication on Prestalia®
City of Industry, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today further progress with its FDA-A...
Source: GlobeNewswire
Date: February, 27 2018 10:14
Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio
City of Industry, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that the Company has entered in...
Source: GlobeNewswire
Date: January, 16 2018 08:40
Marina Biotech Appoints Isaac Blech to its Board of Directors
City of Industry, CA , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today the appointment of Mr. Isaac B...
Source: GlobeNewswire
Date: November, 27 2017 08:30
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
City of Industry, CA, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Peter D. Weinstein, Ph.D.,...
Source: GlobeNewswire
Date: October, 19 2017 08:30
Marina Biotech Appoints Amit Shah as Chief Financial Officer
City of Industry, CA, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Amit Shah will join the co...
Source: GlobeNewswire
Date: October, 05 2017 08:30
Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech's Manufacturing Initiatives
CITY OF INDUSTRY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB:MRNA) (OTCQB:MRNAD) (‘Marina’ or the ‘Company’) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease inters...
Source: GlobeNewswire
Date: August, 21 2017 08:30
Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market
CITY OF INDUSTRY, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB:MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced a 1-for-10 ...
Source: GlobeNewswire
Date: August, 02 2017 08:45
Marina Bio to sell DiLA platform for $1.5M; shares up 5%
Marina Biotech ( MRNA +4.5% ) has signed a binding letter of intent with an unnamed gene-editing biotech firm to sell its DiLA delivery platform for $1.5M. More news on: Marina Biotech, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
Source: SeekingAlpha
Date: July, 25 2017 13:51
Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform
CITY OF INDUSTRY, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB:MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that it ha...
Source: GlobeNewswire
Date: July, 25 2017 12:00
Marina Biotech Acquires DyrctAxess(TM) Technology Platform to Support Sales and Marketing of Prestalia®
CITY OF INDUSTRY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB:MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has...
Source: GlobeNewswire
Date: July, 24 2017 12:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.680.640.680.641,600
2018-08-200.671250.671250.671250.67125126
2018-08-170.640.671250.671250.64814
2018-08-160.6620.690250.690250.659,231
2018-08-150.6250.6350.6350.6253,092

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1761481475.4300Short
2018-08-164,5009,23148.7488Short
2018-08-153,21810,30031.2427Cover
2018-08-098,2009,40087.2340Short
2018-08-061,0001,78456.0538Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRNA.


About Marina Biotech, Inc. (OTC: MRNA)

Logo for Marina Biotech, Inc. (OTC: MRNA)

Marina Biotech, Inc. is a fully integrated, commercial stage biopharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and additional markets. Our portfolio of products focuses on fixed dose combinations FDC in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our approach is meant to reduce clinical risk and accelerate time to market by shortening the clinical development program through leveraging what is already known or can be learned in our proprietary Patient Level Database. We currently have one commercial and three clinical development programs underway: i Prestalia , a single pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S. ii our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT and IT , each of which is an FDC of celecoxib and either lisinopril IT or olmesartan IT iii CEQ , an oral delivery of small interfering RNA against beta catenin, combined with IT to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis and iv CEQ combined with IT to treat Colorectal Cancer.

 

Contact Information

 

 

Current Management

  • Joseph W. Ramelli / CEO
  • Mihir Munsif / COO
  • Amit Bhupendra Shah / CFO
  • Erik Emerson / Chief Commercial Officer
  • Peter D. Weinstein / Chief Legal Officer
  • Larn Hwang / Chief Scientific Officer
  • Vuong Trieu / Executive Chairman
  • Donald A Williams / Independent Director, Audit Committee Member, Compensation Committee Member

Current Share Structure

  • Market Cap: $16,307,981 - 03/09/2018
  • Authorized: 180,000,000 - 09/20/2017
  • Issue and Outstanding: 10,521,278 - 11/13/2017

 


Recent Filings from (OTC: MRNA)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 27 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 03 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 05 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (OTC: MRNA)

Daily Technical Chart for (OTC: MRNA)


Stay tuned for daily updates and more on (OTC: MRNA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MRNA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of MRNA and does not buy, sell, or trade any shares of MRNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/